OraSure (OSUR) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	5-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'OSUR	'
Entity Registrant Name	'ORASURE TECHNOLOGIES INC	'
Entity Central Index Key	'0001116463	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	55,841,785

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash	$84,193	$93,191
Accounts receivable, net of allowance for doubtful accounts of $284 and $299	13,287	12,957
Inventories	11,994	11,444
Prepaid expenses	2,016	1,712
Deferred income taxes	68	71
Other current assets	197	200
Total current assets	111,755	119,575
PROPERTY AND EQUIPMENT, net	17,826	17,933
INTANGIBLE ASSETS, net	20,659	22,226
GOODWILL	22,860	23,782
OTHER ASSETS	980	729
TOTAL ASSETS	174,080	184,245
CURRENT LIABILITIES:	'	'
Accounts payable	4,114	4,834
Deferred revenue	954	1,119
Accrued expenses	9,902	13,032
Total current liabilities	14,970	18,985
OTHER LIABILITIES	961	677
DEFERRED INCOME TAXES	3,435	3,437
COMMITMENTS AND CONTINGENCIES (Note 6)	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock, par value $.000001, 25,000 shares authorized, none issued	'	'
Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding	'	'
Additional paid-in capital	339,651	338,674
Accumulated other comprehensive loss	-5,575	-3,797
Accumulated deficit	-179,362	-173,731
Total stockholders' equity	154,714	161,146
Total liabilities and stockholders' equity	$174,080	$184,245

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$284	$299
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	55,842	55,632
Common stock, shares outstanding	55,842	55,632

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
NET REVENUES:	'	'
Product	$23,537	$20,962
Licensing and product development	'	202
Total revenue	23,537	21,164
COST OF PRODUCTS SOLD	9,610	9,135
Gross profit	13,927	12,029
OPERATING EXPENSES:	'	'
Research and development	2,481	3,357
Sales and marketing	11,340	13,874
General and administrative	5,724	5,387
Total operating expenses	19,545	22,618
Operating loss	-5,618	-10,589
OTHER INCOME (EXPENSE)	118	-47
Loss before income taxes	-5,500	-10,636
INCOME TAX EXPENSE (BENEFIT)	131	-410
NET LOSS	($5,631)	($10,226)
LOSS PER SHARE:	'	'
BASIC	($0.10)	($0.18)
DILUTED	($0.10)	($0.18)
SHARES USED IN COMPUTING LOSS PER SHARE:	'	'
BASIC	55,762	55,449
DILUTED	55,762	55,449

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'
Net loss	($5,631)	($10,226)
OTHER COMPREHENSIVE LOSS	'	'
Currency translation adjustments	-1,778	-1,125
Other comprehensive loss	-1,778	-1,125
COMPREHENSIVE LOSS	($7,409)	($11,351)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
OPERATING ACTIVITIES:	'	'
Net loss	($5,631)	($10,226)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation	1,406	1,394
Depreciation and amortization	1,539	1,602
Deferred income taxes	131	-410
Changes in assets and liabilities	'	'
Accounts receivable	-402	512
Inventories	-586	-312
Prepaid expenses and other assets	-280	-1,545
Accounts payable	-683	2,263
Deferred revenue	-153	37
Accrued expenses and other liabilities	-3,009	-989
Net cash used in operating activities	-7,668	-7,674
INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	-647	-480
Net cash used in investing activities	-647	-480
FINANCING ACTIVITIES:	'	'
Proceeds from exercise of stock options	93	301
Repurchase of common stock	-521	-743
Net cash used in financing activities	-428	-442
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	-255	-16
NET DECREASE IN CASH	-8,998	-8,612
CASH, BEGINNING OF PERIOD	93,191	87,888
CASH, END OF PERIOD	84,193	79,276
Cash paid for:	'	'
Income taxes	$40	$27

The_Company

The Company	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
The Company	'
	1	The Company
	We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are sold to retail pharmacies and mass merchandisers as well as to consumers over the internet.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.
	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
	Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
			March 31, 2014				December 31, 2013
	Raw materials		$	6,815			$	6,700
	Work in process			890				833
	Finished goods			4,289				3,911
			$	11,994			$	11,444
	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.
	Intangible Assets. Intangible assets consist of the following:
					March 31, 2014
			Amortization		Gross				Accumulated			Net
			Period (Years)						Amortization
	Customer list		10		$	11,338			$	(2,866	)	$	8,472
	Patents and product rights		10-Mar			10,449				(7,601	)		2,848
	Acquired technology		7			8,807				(3,132	)		5,675
	Tradename		15			4,346				(759	)		3,587
	Non-compete agreements		3-Jan			615				(538	)		77
					$	35,555			$	(14,896	)	$	20,659
					31-Dec-13
			Amortization		Gross				Accumulated			Net
			Period (Years)						Amortization
	Customer list		10		$	11,795			$	(2,701	)	$	9,094
	Patents and product rights		10-Mar			10,449				(7,466	)		2,983
	Acquired technology		7			9,162				(2,952	)		6,210
	Tradename		15			4,521				(715	)		3,806
	Non-compete agreements		3-Jan			787				(654	)		133
					$	36,714			$	(14,488	)	$	22,226
	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.
	The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.
	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
	Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.
	Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.
	We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
	Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.
	Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
	Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	3	Stockholders’ Equity
	Stock-Based Awards
	We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.
	Total compensation cost related to stock options for the three months ended March 31, 2014 and 2013 was $719 and $662, respectively. Net cash proceeds from the exercise of stock options were $93 and $301 for the three months ended March 31, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.
	The following table summarizes the stock option activity for the three months ended March 31, 2014:
			Options
	Outstanding on January 1, 2014			5,271
	Granted			1,168
	Exercised			(22	)
	Expired			(319	)
	Forfeited			(70	)
	Outstanding on March 31, 2014			6,028
	Compensation cost of $687 and $732 related to restricted shares was recognized during the three months ended March 31, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the three months ended March 31, 2014 and 2013, 89 and 106 shares, respectively, with aggregate values of $521 and $743, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.
	The following table summarizes restricted stock award activity for the three months ended March 31, 2014:
			Shares
	Issued and unvested, January 1, 2014			653
	Granted			403
	Vested			(276	)
	Forfeited			(16	)
	Issued and unvested, March 31, 2014			764

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Accrued Expenses	'
	4	Accrued Expenses
			March 31, 2014		December 31, 2013
	Payroll and related benefits		$	2,763	$	5,827
	Royalties			4,813		4,374
	Professional fees			733		749
	Other			1,593		2,082
			$	9,902	$	13,032

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	5	Income Taxes
	During the three months ended March 31, 2014, we recorded foreign deferred tax expense of $131. During the three months ended March 31, 2013, we recorded a foreign deferred tax benefit of $410. The foreign deferred tax benefit is associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2013. The 2013 income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.
	In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of March 31, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three months ended March 31, 2014 and 2013.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	6	Commitments and Contingencies
	From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Business Segment Information	'
	7	Business Segment Information
	We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing, as well as, products sold into the academic research market, which consists of research laboratories, universities and hospitals.
	We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.
	The following table summarizes segment information for the three months ended March 31, 2014 and 2013.
			Three Months Ended March 31,
			2014			2013
	Net revenues:
	OSUR		$	17,778		$	17,232
	DNAG			5,759			3,932
	Total		$	23,537		$	21,164
	Operating income (loss):
	OSUR		$	(6,394	)	$	(10,040	)
	DNAG			776			(549	)
	Total		$	(5,618	)	$	(10,589	)
	Depreciation and amortization:
	OSUR		$	776		$	777
	DNAG			763			825
	Total		$	1,539		$	1,602
	Capital expenditures:
	OSUR		$	439		$	243
	DNAG			208			237
	Total		$	647		$	480
			March 31, 2014			December 31, 2013
	Total assets:
	OSUR		$	122,675		$	130,848
	DNAG			51,405			53,397
	Total		$	174,080		$	184,245
	Our products are sold principally in the United States and Europe.
	The following table represents total revenues by geographic area, based on the location of the customer:
			Three Months Ended March 31,
			2014			2013
	United States		$	17,406		$	16,040
	Europe			4,001			2,846
	Other regions			2,130			2,278
			$	23,537		$	21,164
	The following table represents total long-lived assets by geographic area:
			March 31, 2014			December 31, 2013
	United States		$	16,729		$	16,925
	Canada			1,069			975
	Other regions			28			33
			$	17,826		$	17,933

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation and Basis of Presentation	'
	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.
Use of Estimates	'
	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.
Inventories	'
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
		March 31, 2014				December 31, 2013
	Raw materials	$	6,815			$	6,700
	Work in process		890				833
	Finished goods		4,289				3,911
		$	11,994			$	11,444
Property and Equipment	'
	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.
Intangible Assets	'
	Intangible Assets. Intangible assets consist of the following:
				March 31, 2014
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	11,338			$	(2,866	)	$	8,472
	Patents and product rights	10-Mar			10,449				(7,601	)		2,848
	Acquired technology	7			8,807				(3,132	)		5,675
	Tradename	15			4,346				(759	)		3,587
	Non-compete agreements	3-Jan			615				(538	)		77
				$	35,555			$	(14,896	)	$	20,659
				31-Dec-13
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	11,795			$	(2,701	)	$	9,094
	Patents and product rights	10-Mar			10,449				(7,466	)		2,983
	Acquired technology	7			9,162				(2,952	)		6,210
	Tradename	15			4,521				(715	)		3,806
	Non-compete agreements	3-Jan			787				(654	)		133
				$	36,714			$	(14,488	)	$	22,226
Goodwill	'
	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.
	The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.
Revenue Recognition	'
	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
Customer Sales Returns and Allowances	'
	Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
Deferred Revenue	'
	Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.
Customer and Vendor Concentrations	'
	Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.
	We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Loss Per Share	'
	Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.
Foreign Currency Translation	'
	Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Inventories	'
	Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:
		March 31, 2014				December 31, 2013
	Raw materials	$	6,815			$	6,700
	Work in process		890				833
	Finished goods		4,289				3,911
		$	11,994			$	11,444
Intangible Assets	'
	Intangible assets consist of the following:
				March 31, 2014
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	11,338			$	(2,866	)	$	8,472
	Patents and product rights	10-Mar			10,449				(7,601	)		2,848
	Acquired technology	7			8,807				(3,132	)		5,675
	Tradename	15			4,346				(759	)		3,587
	Non-compete agreements	3-Jan			615				(538	)		77
				$	35,555			$	(14,896	)	$	20,659
				31-Dec-13
		Amortization		Gross				Accumulated			Net
		Period (Years)						Amortization
	Customer list	10		$	11,795			$	(2,701	)	$	9,094
	Patents and product rights	10-Mar			10,449				(7,466	)		2,983
	Acquired technology	7			9,162				(2,952	)		6,210
	Tradename	15			4,521				(715	)		3,806
	Non-compete agreements	3-Jan			787				(654	)		133
				$	36,714			$	(14,488	)	$	22,226

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Summary of Company's Stock Option Activity	'
	The following table summarizes the stock option activity for the three months ended March 31, 2014:
		Options
	Outstanding on January 1, 2014		5,271
	Granted		1,168
	Exercised		(22	)
	Expired		(319	)
	Forfeited		(70	)
	Outstanding on March 31, 2014		6,028
Summary of Restricted Stock Award Activity	'
	The following table summarizes restricted stock award activity for the three months ended March 31, 2014:
		Shares
	Issued and unvested, January 1, 2014		653
	Granted		403
	Vested		(276	)
	Forfeited		(16	)
	Issued and unvested, March 31, 2014		764

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Expenses	'
		March 31, 2014		December 31, 2013
	Payroll and related benefits	$	2,763	$	5,827
	Royalties		4,813		4,374
	Professional fees		733		749
	Other		1,593		2,082
		$	9,902	$	13,032

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Summary of Segment Information	'
	The following table summarizes segment information for the three months ended March 31, 2014 and 2013.
		Three Months Ended March 31,
		2014			2013
	Net revenues:
	OSUR	$	17,778		$	17,232
	DNAG		5,759			3,932
	Total	$	23,537		$	21,164
	Operating income (loss):
	OSUR	$	(6,394	)	$	(10,040	)
	DNAG		776			(549	)
	Total	$	(5,618	)	$	(10,589	)
	Depreciation and amortization:
	OSUR	$	776		$	777
	DNAG		763			825
	Total	$	1,539		$	1,602
	Capital expenditures:
	OSUR	$	439		$	243
	DNAG		208			237
	Total	$	647		$	480
		March 31, 2014			December 31, 2013
	Total assets:
	OSUR	$	122,675		$	130,848
	DNAG		51,405			53,397
	Total	$	174,080		$	184,245
Presentation of Total Revenues and Long-Lived Assets by Geographic Area	'
	The following table represents total revenues by geographic area, based on the location of the customer:
		Three Months Ended March 31,
		2014			2013
	United States	$	17,406		$	16,040
	Europe		4,001			2,846
	Other regions		2,130			2,278
		$	23,537		$	21,164
	The following table represents total long-lived assets by geographic area:
		March 31, 2014			December 31, 2013
	United States	$	16,729		$	16,925
	Canada		1,069			975
	Other regions		28			33
		$	17,826		$	17,933

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Share data in Thousands, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jul. 31, 2012

Mar. 31, 2014

Customer

Up Front Payment Arrangement [Member]

Up Front Payment Arrangement [Member]

Accounts Receivable [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

DNA Genotek [Member]

DNA Genotek [Member]

Customer Concentration Risk [Member]

Other Intangible Assets [Member]

Building [Member]

Other Intangible Assets [Member]

Building [Member]

Product Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of plan assets

$1,111,000

'

$677,000

'

'

'

'

'

'

'

'

'

Useful life of building and other assets

'

'

'

'

'

'

'10 years

'40 years

'2 years

'20 years

'

'

Accumulated depreciation of property and equipment

29,081,000

'

28,390,000

'

'

'

'

'

'

'

'

'

Fair value of goodwill

'

'

'

'

'

'

'

'

'

'

'

25,179,000

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

0

'

Percentage of excess of fair value on carrying value

13.00%

'

'

'

'

'

'

'

'

'

'

'

Amount of goodwill at period end

22,860,000

'

23,782,000

'

'

'

'

'

'

'

'

'

Reserve for sales return and allowances

329,000

'

279,000

'

'

'

'

'

'

'

'

'

Deferred revenue

954,000

'

1,119,000

954,000

1,119,000

'

'

'

'

'

'

'

Number of our customers, accounted for significant concentrations

1

'

'

'

'

'

'

'

'

'

'

'

Percentage of concentration risk

'

'

'

'

'

11.00%

'

'

'

'

'

'

Concentration rate of accounts receivable

10.00%

'

'

'

'

'

'

'

'

'

'

'

Significant concentrations in revenues

0

0

'

'

'

'

'

'

'

'

'

'

Number of third-party suppliers to manufacture DNAG's products

'

'

'

'

'

'

'

'

'

'

'

'2

Number of anti-dilutive securities excluded from EPS computation

6,792

5,997

'

'

'

'

'

'

'

'

'

'

Accumulated foreign currency adjustments included in other comprehensive loss amounted

$1,778,000

$1,125,000

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Net [Abstract]	'	'
Raw materials	$6,815	$6,700
Work in process	890	833
Finished goods	4,289	3,911
Inventories	$11,994	$11,444

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	$35,555	$36,714
Accumulated Amortization	-14,896	-14,488
Net	20,659	22,226
Customer List [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'10 years	'10 years
Gross	11,338	11,795
Accumulated Amortization	-2,866	-2,701
Net	8,472	9,094
Patent and Product Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	10,449	10,449
Accumulated Amortization	-7,601	-7,466
Net	2,848	2,983
Patent and Product Rights [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'3 years	'3 years
Patent and Product Rights [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'10 years	'10 years
Acquired Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'7 years	'7 years
Gross	8,807	9,162
Accumulated Amortization	-3,132	-2,952
Net	5,675	6,210
Tradename [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'15 years	'15 years
Gross	4,346	4,521
Accumulated Amortization	-759	-715
Net	3,587	3,806
Non-compete Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	615	787
Accumulated Amortization	-538	-654
Net	$77	$133
Non-compete Agreements [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'1 year	'1 year
Non-compete Agreements [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'3 years	'3 years

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	$1,406	$1,394
Net cash proceeds from the exercise of stock options	93	301
Income tax benefit realized from stock option exercises during period	0	0
Restricted Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	687	732
Vesting of restricted shares, withheld and withholding obligations	89	106
Restricted shares of common stock, aggregate values	521	743
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	719	662
Net cash proceeds from the exercise of stock options	$93	$301

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]	'
Options, Outstanding, Beginning balance	5,271
Options, Outstanding, Granted	1,168
Options, Outstanding, Exercised	-22
Options, Outstanding, Expired	-319
Options, Outstanding, Forfeited	-70
Options, Outstanding, Ending balance	6,028

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Equity [Abstract]	'
Shares, Issued and unvested, Beginning balance	653
Shares, Granted	403
Shares, Vested	-276
Shares, Forfeited	-16
Shares, Issued and unvested, Ending balance	764

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities Current [Abstract]	'	'
Payroll and related benefits	$2,763	$5,827
Royalties	4,813	4,374
Professional fees	733	749
Other	1,593	2,082
Accrued Expenses, Total	$9,902	$13,032

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Foreign deferred tax expense (benefits)	$131	($410)
U.S. federal income tax benefits	0	0
U.S. state income tax benefits	$0	$0

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments of company	2

Business_Segment_Information_S

Business Segment Information - Summary of Segment Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'
Net revenues	$23,537	$21,164	'
Operating income (loss)	-5,618	-10,589	'
Depreciation and amortization	1,539	1,602	'
Capital expenditures	647	480	'
Total assets	174,080	'	184,245
OSUR [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	17,778	17,232	'
Operating income (loss)	-6,394	-10,040	'
Depreciation and amortization	776	777	'
Capital expenditures	439	243	'
Total assets	122,675	'	130,848
DNAG [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net revenues	5,759	3,932	'
Operating income (loss)	776	-549	'
Depreciation and amortization	763	825	'
Capital expenditures	208	237	'
Total assets	$51,405	'	$53,397

Business_Segment_Information_P

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Revenues	$23,537	$21,164	'
Long-lived assets	17,826	'	17,933
United States [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Revenues	17,406	16,040	'
Long-lived assets	16,729	'	16,925
Europe [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Revenues	4,001	2,846	'
Other Regions [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Revenues	2,130	2,278	'
Long-lived assets	28	'	33
Canada [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Long-lived assets	$1,069	'	$975